Short-term Clinical Observations of 73 Nasopharyngeal Carcinoma Patients Treated with TomoTherapy
L. Ma,L. Du,L. Feng,G. Zhou,B. Qu,G. Ren,S. Xu,C. Xie,X. Zhang,F. Li
DOI: https://doi.org/10.1016/j.ijrobp.2010.07.1116
2010-01-01
Abstract:To evaluate the preliminary short-term clinical outcome of a total of 73 nasopharyngeal carcinoma (NPC) patients treated with the first TomoTherapy in China. Between September 2007 and October 2009, 56 male and 17 female (total 73) newly diagnosed NPC patients were treated with TomoTherapy with Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT) protocols. The median age was 43 (11∼76) years, with 3 squamous and 70 non-keratinizing carcinomas. The distributions of clinical stages according to the Fouzhou 92s Staging System were: 7, 28, 23, and 15 for Stage I, II, II, and IVa, respectively. Patients were immobilized in a thermoplastic mask from head to shoulders, and 3 mm thickness CT scan slices of the head and neck protocol were obtained for targets and OAR contouring. The prescription dose was 70 - 74 Gy in 33 fractions to gross tumor volume and positive lymph nodes, with 60 - 62.7 Gy in 33 fractions to high risk planning target volume, while delivering 52 - 56.1 Gy in 33 fractions to low risk planning target volume. Among all those NPC cases, 24 were treated with radiation therapy as a single modality, 18 with concurrent chemo-radiotherapy, 24 with EGFR monoclonal antibody (Cetuximab or Nimotuzumab), and 7 combined with chemotherapy and EGFR monoclonal antibody. Preliminary tumor response was noted. Acute side-effects and late xerostomia were evaluated with the established RTOG/EORTC criteria. Average beam-on-time was 468.8 sec/F (396.7 - 696.1 sec). The median follow-up time was 14.8 months. Acute side-effects were evaluated as the following: skin toxicities of Grade 0, 1, 2, and 3 were 2.7%, 76.7%, 13.8%, and 6.8%; mucositis of Grade 0, 1, 2, and 3 were 1.4%, 32.9%, 60.2%, and 5.5%; xerostomia of grade 0, 1, 2, and 3 were 4.0%, 45.3%, 50.7 %, and 0; leucopenia of Grade 0, 1, 2, 3, and 4 were 56.2%, 15.0%, 21.9%, 5.5%, and 1.4%; thrombocytopenia of Grade 0, 1, 2, and 3 were 689.0%, 9.6%, 1.4%, and 0; anemia of Grade 0, 1, 2, and 3 were 97.2%, 0, 2.8%, and 0, respectively. The remission rates (CR+PR) of primary tumor and positive lymph nodes were 91.8% and 98.1%. Four months after radiation therapy xerostomia of Grade 0, 1, and 2 were 4.2%, 87.5%, and 8.3%, respectively. One-year relapse free survival (RFS) is 95.6%, distant metastasis free survival (DMFS) is 97.2%, and overall survival (OS) is 94.8%. The incidence of severe acute toxicities and late xerostomia is relatively minor for NPC patients treated with TomoTherapy which presents great advantages from both planning and delivery aspects. For NPC with large tumor volume and nodal involvement, Tomotherapy presents clinical advantages compared to conventional delivery methods. Long-term clinical outcome for these patients are under further investigation.